Addex Therapeutics Ltd (ADDXF)
| Previous Close | 0.9900 |
| Open | 0.9900 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.9900 - 0.9900 |
| 52 Week Range | 0.9900 - 1.6500 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 32.099M |
| Beta (5Y Monthly) | 1.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Addex Announces Participation in the H.C. Wainwright Global Investment Conference
Geneva, Switzerland, May 19, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will be virtually attending the H.C. Wainwright Global Investment Conference taking place May 23 - 26, 2022. Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate update and discusses recent developments at
- GlobeNewswire
Addex Announces Participation in the 22nd Bio€quity Europe Conference
Geneva, Switzerland, May 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, and Dr. Robert Lütjens, Head of Discovery – Biology, will be attending 22nd Bio€quity Europe Conference taking place May 16 - 18, 2022, in Milan, Italy. Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate
- GlobeNewswire
Addex Shareholders Approve All Resolutions at Annual General Meeting
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2022 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all of the proposals of the board of directors in its 2022 Annual General Meeting (AGM). In line with the Swiss Federal Council COVID-19 Ordinance 3, the company decided to require its shareholders not atten
